InterVenn Investigator Initiated Research Program in Glycoproteomics

News

November 10, 2022 - InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
Read more

October 26, 2022 - Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences
Read more

October 5, 2022 - InterVenn Biosciences Co-Founder Carolyn Bertozzi Awarded Nobel Prize in Chemistry
Read more

October 4, 2022 - InterVenn Biosciences Expands Board of Directors with Dr. Jason Myers and Carol Berry to Support Next Phase of Growth
Read more

August 2, 2022 - InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study
Read more

July 21, 2022 - InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes
Read more

June 2, 2022 - InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma as a Novel Liquid Biopsy Test to Improve Assessment of Benefit to Cancer Patients
Read more

June 1, 2022 - InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums to Introduce a Glycoproteomic Option for Liquid Biopsies
Read more

May 6, 2022 - InterVenn to Present New Clinical Data at ASCO 2022
Read more

May 5, 2022 - Bank of America 2022 Healthcare Conference, May 10, 2022 at 2:00pm PT / 5:00pm ET
Click here for webcast

Company Events and Presentations

November 16, 2022 - Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum (November 17, 2:30 PM ET)
Listen to the webcast

March 4, 2022 - Cowen 42nd Annual Health Care Conference, March 7, 2022 at 12:50 PM ET / 9:50 AM PT
Click here for webcast

January 5, 2022 - InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, the company’s CEO and Co-Founder, is scheduled to present at the J.P. Morgan 40th Annual Healthcare Conference on January 12, 2022, from 3:00 – 3:25 pm EST.
Read more

November 11, 2021 - InterVenn Biosciences today announced that company management will participate at the following virtual investor conferences

A live webcast of the Stifel event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/ and will be available for 90 days thereafter.

Investors